Developer docs
API playgroundTry for free, no card

Search company profiles

Grünelabs

Full company profile

uuid004j2ps

Namestring
Grünelabs
Legal namestring
Grüne Labs
Websiteurl
grunelabs.com
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPando, Canelones, Uruguay
HQ citystring
Pando, Canelones
HQ countrystring
Uruguay
HQ regionstring
Latin America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical cannabis extracts, phytopharmaceutical manufacturing, full-spectrum cannabis, cannabis cultivation services, cannabis formulation products
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Medical Cannabis / Phytopharmaceuticals
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1B2B Extract Sales
TypeOne Time License
Description

Sale of high-quality full-spectrum cannabis extracts to business partners in the pharmaceutical industry.

grunelabs.com
2B2C Finished Product Sales
TypeOne Time License
Description

Sale of finished cannabis-based formulations (Meroflex product line) directly to patients via pharmacies and individual imports.

grunelabs.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Meroflex 1:1
Description

Cannabis sativa L. extract oral drops solution — CBD 1:1 THC Full Spectrum, with 2.7 g CBD and 2.5 g THC per 100 mL, in a 30 mL blue glass dropper bottle.

grunelabs.com
+1 more record
Core offering1 text field

Grünelabs is a phytopharmaceutical company that produces full-spectrum medical cannabis extracts and finished formulations under a clone-to-bottle model. It cultivates Cannabis sativa L. using proprietary genetics, then performs extraction, formulation, and bottling in-house at GMP-certified facilities. The company sells bulk extracts to pharmaceutical partners (B2B) and finished oral drop formulations (Meroflex line) directly to patients via pharmacies and individual import mechanisms (B2C).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Full-spectrum extract available in Uruguay and Brazil, with plans to expand to local Brazilian pharmacies and European markets
+1 more record
Product overview1 text field

Grünelabs is a phytopharmaceutical company offering a portfolio of two proprietary full-spectrum cannabis extract products—Meroflex 1:1 and Meroflex 2:1—both delivered as oral drop solutions. The company operates a clone-to-bottle model, providing cultivation, extraction, and formulation services (B2B extracts and B2C finished products). Products are currently available in Uruguay and Brazil, with expansion to European markets planned through its Portugal facility.

Product and service4 records
1Meroflex 1:1
CategoryMedical Cannabis Formulation
Description

Full-spectrum Cannabis sativa L. extract oral drops solution containing 2.7 g CBD and 2.5 g THC per 100 mL in a 1:1 ratio, presented in a 30 mL blue glass dropper bottle. Indicated for adults under medical supervision for improvement of spasticity symptoms, especially in Multiple Sclerosis. Available in Uruguay and Brazil.

2Meroflex 2:1
CategoryMedical Cannabis Formulation
Description

Full-spectrum Cannabis sativa L. extract oral drops solution containing 2.2 g CBD and 0.9 g THC per 100 mL in a 2:1 ratio, presented in a 30 mL blue glass dropper bottle. Available in Uruguay and Brazil under medical prescription.

3B2B Full-Spectrum Cannabis Extracts
CategoryCannabis Extract Supply
Description

Sale of high-quality full-spectrum cannabis extracts in bulk to pharmaceutical industry partners requiring specific biogenetic and chemical characteristics. Produced under GMP standards from proprietary Cannabis sativa L. genetics.

4Medical Cannabis Buds (Bulk / Dried Flower)
CategoryMedical Cannabis Raw Material
Description

Cannabis buds and dried flower products offered as part of the company's phytopharmaceutical product portfolio, with planned production steps from cloning to drying and trimming at the Portuguese facility.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The company's R&D department collaborates with the University of the Republic in Uruguay, receiving support for research and innovation in cannabis cultivation and extraction. This partnership provides access to a global network of university scientists and fosters knowledge exchange.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

ANII provides research and innovation support to GrüneLabs' R&D department, contributing to the advancement of cannabis cultivation and extraction science in Uruguay.

3Local Universities (Portugal)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration planned with local Portuguese universities to establish a research center focused on advancing innovation in cannabis cultivation, extraction, and final preparation. This partnership is a key component of the company's strategy to position itself as a global leader in medicinal cannabis services.

grunelabs.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Khiron is a Latin American (Colombian/now Canadian-listed) medical cannabis company with cultivation, extraction, and finished product distribution across multiple LatAm countries including Brazil. Comparable in vertical integration and Brazil/LatAm strategy.

TypeBroad incumbent
Description

Jazz Pharmaceuticals markets Sativex (nabiximols) for Multiple Sclerosis spasticity, the same primary indication as GrüneLabs' Meroflex products. A direct botanical cannabinoid therapeutic competitor with global commercialization muscle.

TypeDirect peer
Description

MediPharm Labs is a Canadian GMP-certified cannabis extraction specialist focused on producing cannabis concentrates and APIs for pharmaceutical partners. Closely comparable as a pure-play extraction/pharma-supply peer in the medical cannabis value chain.

TypeDirect peer
Description

Clever Leaves is a Colombian-based GMP-certified medical cannabis producer serving European and Latin American markets with cultivated flower and extracts. Direct comparator to GrüneLabs in being a LatAm-headquartered cannabis cultivator/extractor targeting pharma export markets.

TypeBroad incumbent
Description

Charlotte's Web is a US-focused full-spectrum hemp/CBD wellness company producing botanical extract products with strong consumer and pharmacy distribution. Comparable in full-spectrum botanical extract manufacturing and brand-led medical/therapeutic positioning.

TypeDirect peer
Description

ICC Labs was a Latin American (originally Uruguayan-domiciled) medical cannabis producer with GMP operations focused on regional supply. Comparable as a historically Uruguay-anchored cannabis producer serving regional medical markets.

TypeBroad incumbent
Description

OrganiGram is a Canadian licensed producer with GMP-certified cultivation and processing capabilities supplying medical cannabis markets, including expansion into European and international medical channels. Comparable as a multi-country licensed medical cannabis producer.

8Tilray Brands
TypeBroad incumbent
Description

Tilray is a global cannabis and pharmaceutical-grade cannabis producer with GMP-certified operations across multiple countries including Portugal and Argentina, supplying medical markets in Europe and Latin America. Larger broad incumbent operating in the same medical cannabis category.

TypeBroad incumbent
Description

Canopy Growth operates one of the largest medical cannabis footprints including Spectrum Therapeutics medical brands and EU-GMP certified facilities across Europe and Latin America. Major broad incumbent overlapping with GrüneLabs' medical cannabis positioning.

TypeBroad incumbent
Description

Aurora Cannabis is a major global medical cannabis producer with EU-GMP certified cultivation and processing operations across Europe and the Americas, supplying dried flower and extracts to medical markets. Comparable as a large GMP-certified medical cannabis producer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Grünelabs

Medical Cannabis / Phytopharmaceuticalsgrunelabs.com

Grünelabs firmographics

Firmographics
Name
Grünelabs
Legal name
Grüne Labs
Website
https://grunelabs.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Where Grünelabs is headquartered

Location

Headquarters

HQ city
Pando, Canelones
HQ country
Uruguay
HQ region
Latin America

Offices2 records

Markets served

Grünelabs business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. B2B Extract Sales: Sale of high-quality full-spectrum cannabis extracts to business partners in the pharmaceutical industry.
  2. B2C Finished Product Sales: Sale of finished cannabis-based formulations (Meroflex product line) directly to patients via pharmacies and individual imports.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Grünelabs product offering

Product offering

Core offering

Grünelabs is a phytopharmaceutical company that produces full-spectrum medical cannabis extracts and finished formulations under a clone-to-bottle model. It cultivates Cannabis sativa L. using proprietary genetics, then performs extraction, formulation, and bottling in-house at GMP-certified facilities. The company sells bulk extracts to pharmaceutical partners (B2B) and finished oral drop formulations (Meroflex line) directly to patients via pharmacies and individual import mechanisms (B2C).

Product overview

Grünelabs is a phytopharmaceutical company offering a portfolio of two proprietary full-spectrum cannabis extract products—Meroflex 1:1 and Meroflex 2:1—both delivered as oral drop solutions. The company operates a clone-to-bottle model, providing cultivation, extraction, and formulation services (B2B extracts and B2C finished products). Products are currently available in Uruguay and Brazil, with expansion to European markets planned through its Portugal facility.

Differentiator

Problem solved

Functional benefit

Brands

  • Meroflex 1:1: Cannabis sativa L. extract oral drops solution — CBD 1:1 THC Full Spectrum, with 2.7 g CBD and 2.5 g THC per 100 mL, in a 30 mL blue glass dropper bottle.
  • Meroflex 2:1

Products and services

  • Meroflex 1:1 Full-spectrum Cannabis sativa L. extract oral drops solution containing 2.7 g CBD and 2.5 g THC per 100 mL in a 1:1 ratio, presented in a 30 mL blue glass dropper bottle. Indicated for adults under medical supervision for improvement of spasticity symptoms, especially in Multiple Sclerosis. Available in Uruguay and Brazil.
  • Meroflex 2:1 Full-spectrum Cannabis sativa L. extract oral drops solution containing 2.2 g CBD and 0.9 g THC per 100 mL in a 2:1 ratio, presented in a 30 mL blue glass dropper bottle. Available in Uruguay and Brazil under medical prescription.
  • B2B Full-Spectrum Cannabis Extracts Sale of high-quality full-spectrum cannabis extracts in bulk to pharmaceutical industry partners requiring specific biogenetic and chemical characteristics. Produced under GMP standards from proprietary Cannabis sativa L. genetics.
  • Medical Cannabis Buds (Bulk / Dried Flower) Cannabis buds and dried flower products offered as part of the company's phytopharmaceutical product portfolio, with planned production steps from cloning to drying and trimming at the Portuguese facility.

Quantifiable outcome

  • Full-spectrum extract available in Uruguay and Brazil, with plans to expand to local Brazilian pharmacies and European markets
  • +1 more outcomes

Companies that use Grünelabs

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Grünelabs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Grünelabs partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • University of the Republic (Universidad de la República)coreStrategic or Co-development PartnerThe company's R&D department collaborates with the University of the Republic in Uruguay, receiving support for research and innovation in cannabis cultivation and extraction. This partnership provides access to a global network of university scientists and fosters knowledge exchange.
  • National Research and Innovation Agency of Uruguay (ANII)minorStrategic or Co-development PartnerANII provides research and innovation support to GrüneLabs' R&D department, contributing to the advancement of cannabis cultivation and extraction science in Uruguay.
  • Local Universities (Portugal)coreStrategic or Co-development PartnerCollaboration planned with local Portuguese universities to establish a research center focused on advancing innovation in cannabis cultivation, extraction, and final preparation. This partnership is a key component of the company's strategy to position itself as a global leader in medicinal cannabis services.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Grünelabs competitors and assessment

Company assessment

Direct peers

  • Khiron Life Sciences: Khiron is a Latin American (Colombian/now Canadian-listed) medical cannabis company with cultivation, extraction, and finished product distribution across multiple LatAm countries including Brazil. Comparable in vertical integration and Brazil/LatAm strategy.
  • MediPharm Labs: MediPharm Labs is a Canadian GMP-certified cannabis extraction specialist focused on producing cannabis concentrates and APIs for pharmaceutical partners. Closely comparable as a pure-play extraction/pharma-supply peer in the medical cannabis value chain.
  • Clever Leaves: Clever Leaves is a Colombian-based GMP-certified medical cannabis producer serving European and Latin American markets with cultivated flower and extracts. Direct comparator to GrüneLabs in being a LatAm-headquartered cannabis cultivator/extractor targeting pharma export markets.
  • ICC Labs (now part of Aurora/ICANN): ICC Labs was a Latin American (originally Uruguayan-domiciled) medical cannabis producer with GMP operations focused on regional supply. Comparable as a historically Uruguay-anchored cannabis producer serving regional medical markets.

Broad incumbents

  • Jazz Pharmaceuticals (GW Pharmaceuticals legacy): Jazz Pharmaceuticals markets Sativex (nabiximols) for Multiple Sclerosis spasticity, the same primary indication as GrüneLabs' Meroflex products. A direct botanical cannabinoid therapeutic competitor with global commercialization muscle.
  • Charlotte's Web: Charlotte's Web is a US-focused full-spectrum hemp/CBD wellness company producing botanical extract products with strong consumer and pharmacy distribution. Comparable in full-spectrum botanical extract manufacturing and brand-led medical/therapeutic positioning.
  • Organigram / OrganiGram Global: OrganiGram is a Canadian licensed producer with GMP-certified cultivation and processing capabilities supplying medical cannabis markets, including expansion into European and international medical channels. Comparable as a multi-country licensed medical cannabis producer.
  • Tilray Brands: Tilray is a global cannabis and pharmaceutical-grade cannabis producer with GMP-certified operations across multiple countries including Portugal and Argentina, supplying medical markets in Europe and Latin America. Larger broad incumbent operating in the same medical cannabis category.
  • Canopy Growth (now Canopy USA / acquired by Tilray pending): Canopy Growth operates one of the largest medical cannabis footprints including Spectrum Therapeutics medical brands and EU-GMP certified facilities across Europe and Latin America. Major broad incumbent overlapping with GrüneLabs' medical cannabis positioning.
  • Aurora Cannabis: Aurora Cannabis is a major global medical cannabis producer with EU-GMP certified cultivation and processing operations across Europe and the Americas, supplying dried flower and extracts to medical markets. Comparable as a large GMP-certified medical cannabis producer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Grünelabs social profiles

Digital presence

Grünelabs compliance and trust

Trust signal

Compliance3 records

Grünelabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Grünelabs leadership team

Management profile

Number of profiles

Grünelabs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Grünelabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grünelabs

What does Grünelabs do?

Grünelabs is a phytopharmaceutical company that produces full-spectrum medical cannabis extracts and finished formulations under a clone-to-bottle model. It cultivates Cannabis sativa L. using proprietary genetics, then performs extraction, formulation, and bottling in-house at GMP-certified facilities. The company sells bulk extracts to pharmaceutical partners (B2B) and finished oral drop formulations (Meroflex line) directly to patients via pharmacies and individual import mechanisms (B2C).

Is Grünelabs a public or private company?

Grünelabs is a private company. It is classified as unknown and is currently operating.

When was Grünelabs founded?

Grünelabs was founded in 2019. It employs 1 to 10 people.

Where is Grünelabs based?

Grünelabs is headquartered in Pando, Canelones, Uruguay, in the Latin America region.

How does Grünelabs make money?

Two revenue lines are on record. B2B Extract Sales are the primary driver. The others are B2C Finished Product Sales.

Who are Grünelabs's main competitors?

Direct peers on record are Khiron Life Sciences, MediPharm Labs, Clever Leaves and ICC Labs (now part of Aurora/ICANN). Broad incumbents are Jazz Pharmaceuticals (GW Pharmaceuticals legacy), Charlotte's Web, Organigram / OrganiGram Global, Tilray Brands, Canopy Growth (now Canopy USA / acquired by Tilray pending) and Aurora Cannabis.

Does Grünelabs have an API?

No public API is recorded for Grünelabs.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales